Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 746

Sort by

Sort Order Select

Journal Articles

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Amandeep Kaur, PhD, Katherine M Hannan, PhD, Samina Nazir, MSc, Kylee H Maclachlan, FRACP,FRCPA, Gretchen Poortinga, PhD, Si Ming Man, PhD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Ross D Hannan, PhD, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 2360.

https://doi.org/10.1182/blood-2019-121713

Published: 2019

Journal Articles

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Melissa Castiglione, BS, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 2485.

https://doi.org/10.1182/blood-2019-131074

Published: 2019

Journal Articles

Choosing Wisely: Optimizing Outpatient Cancer Care and Conserving Resources with a New Algorithm to Report Automated ANC Results in the Presence of Analyzer Flags

Maly Fenelus, MD MPH, Ryan M Golden, MLS(ASCP), Tamiqua Graham, MLS(ASCP), Rachel J So, Jessica Lynn Bautista, BS, MT(ASCP), Ellinor I.B. Peerschke, PhD

Blood (2019) 134 (Supplement_1): 4683.

https://doi.org/10.1182/blood-2019-128963

Published: 2019

Journal Articles

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Blood (2019) 134 (Supplement_1): 4805.

https://doi.org/10.1182/blood-2019-128743

Published: 2019

Journal Articles

Optimal Use of Thai Sinlek Rice (IR) Provides the Nutraceutical Effect on Erythropoiesis in Rats

Pimpisid Koonyosying, PhD, Ben Flemming, BSc, Supachai Ekwattanakit, PhDMD, Vip Viprakasit, MD DPhil, Suthat Fucharoen, MD, Somdet Srichairatanakool, PhD

Blood (2019) 134 (Supplement_1): 4808.

https://doi.org/10.1182/blood-2019-129679

Published: 2019

Journal Articles

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 825.

https://doi.org/10.1182/blood-2019-121751

Published: 2019

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1319.

https://doi.org/10.1182/blood-2019-131394

Published: 2019

Journal Articles

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Lauren Pommert, MDMS, Deepa Bhojwani, MD, Richard Sposto, PhD, Ellynore Florendo, Eric Schafer, MD, Nathan Gossai, MD, Van Thu Huynh, MD, Sridhar Rao, MD PhD, Michael J. Burke, MD

Blood (2019) 134 (Supplement_1): 1325.

https://doi.org/10.1182/blood-2019-127298

Published: 2019

Journal Articles

Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Rabia Shahswar, MD, Gernot Beutel, MD, Piroska Klement, Alina Rehberg, Razif Gabdoulline, Christian Koenecke, MD, Dominik Markel, MD, Hendrik Eggers, MD, Matthias Eder, MD, Michael Stadler, MD PhD, Lothar Hambach, MD, Steve Ehrlich, MD, Gudrun Gohring, MD, Brigitte Schlegelberger, MD, Arne Trummer, MD, Juergen Krauter, MD, Arnold Ganser, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2019) 134 (Supplement_1): 1359.

https://doi.org/10.1182/blood-2019-125377

Published: 2019

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Shaun Fleming, MBBS,, Cheng-Hong Tsai, MD MSc, Hartmut Döhner, MD, Konstanze Döhner, Elli Papaemmanuil, PhD, Hwei-Fang Tien, MD, PhD, John Reynolds, PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Hsin-An Hou

Blood (2019) 134 (Supplement_1): 1392.

https://doi.org/10.1182/blood-2019-128243

Published: 2019

Journal Articles

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

Veronica A Guerra, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 567.

https://doi.org/10.1182/blood-2019-125970

Published: 2019

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Dijiong Wu, MD, Man Li, PhD, Lianjun Zhang, PhD, Jing Qi, PhD, Chun-Wei David Chen, PhD, Xin He, PhD, Yinghui Zhu, PhD, Haojie Dong, PhD, Jie Sun, PhD, Ling Li, PhD, Guido Marcucci, MD, Ya-Huei Kuo, PhD

Blood (2019) 134 (Supplement_1): 642.

https://doi.org/10.1182/blood-2019-124134

Published: 2019

Journal Articles

Fludarabine in Combination with Busulfan As Pretransplant Conditioning for Platelet Gene Therapy in Murine Hemophilia a with Inhibitors

Yingyu Chen, PhD, Jing Li, MD PhD, Jocelyn A. Schroeder, Weiqing Jing, MD PhD, Jianda Hu, PhD, Qizhen Shi, MD PhD

Blood (2019) 134 (Supplement_1): 1108.

https://doi.org/10.1182/blood-2019-127410

Published: 2019

Journal Articles

Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry

Blood (2019) 134 (Supplement_1): 1083.

https://doi.org/10.1182/blood-2019-122821

Published: 2019

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

NARROW

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Choosing Wisely: Optimizing Outpatient Cancer Care and Conserving Resources with a New Algorithm to Report Automated ANC Results in the Presence of Analyzer Flags

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Optimal Use of Thai Sinlek Rice (IR) Provides the Nutraceutical Effect on Erythropoiesis in Rats

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Fludarabine in Combination with Busulfan As Pretransplant Conditioning for Platelet Gene Therapy in Murine Hemophilia a with Inhibitors

Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only